Skip to main
BCYC
BCYC logo

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 17%
Buy 42%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is positioned favorably in the biopharmaceutical market, particularly with its product candidate, BT1718, and insights from key opinion leaders (KOLs) indicating a potential increase in efficacy with the Zele + Keytruda combination therapy. There is substantial positive feedback suggesting that Zele may offer advantages over Padcev, potentially leading to significant treatment switching in more than half of current Padcev-treated patients if comparative efficacy is confirmed. Additionally, the company’s strategic focus on improving safety and tolerability through its innovative Bicycle design, particularly with therapies like BT5528, has attracted investor interest and highlights the promising future of its product pipeline in oncology.

Bears say

Bicycle Therapeutics PLC faces a challenging outlook due to significant concerns regarding the competitive landscape and the efficacy of its product candidates, particularly BT1718, which could lead to substantial market share erosion. The stock has experienced a decline of 45% year-to-date, attributed to perceived weaknesses in clinical data and broader industry pressures that have created an unforgiving environment for biopharmaceutical firms. Additionally, potential threats from third-party challenges and shifting industry trends towards next-generation therapies could adversely impact the company’s valuation and growth prospects.

BCYC has been analyzed by 12 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 42% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 12 analysts, BCYC has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.